Saquinavir and rifampicin for tuberculosis and AIDS: new considerations. Thiago Silva Torres and Valeria Cavalcanti Rolla, Instituto de Pesquisa Clínica Evandro Chagas–Fundação Oswaldo Cruz, Infectious Diseases Department, Rio de Janeiro, Brazil. In reply. Andy Gray, on behalf of the START Project, Department of Therapeutics and Medicines Management, University of KwaZulu-Natal, Durban, South Africa, and Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa; and Salim S. Abdool Karim, on behalf of the START Project, Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa, and Department of Epidemiology, Columbia University, New York, USA.